Shares of Crispr Therapeutics AG (NASDAQ:CRSP) have been given a consensus rating of “Buy” by the eighteen brokerages that are presently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $72.86.
A number of brokerages have recently issued reports on CRSP. William Blair raised shares of Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, November 19th. TheStreet raised shares of Crispr Therapeutics from a “d” rating to a “c” rating in a research note on Monday, October 28th. ValuEngine cut shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday. BidaskClub cut shares of Crispr Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday. Finally, Canaccord Genuity increased their price objective on shares of Crispr Therapeutics from $72.00 to $80.00 and gave the stock a “positive” rating in a research note on Wednesday, November 20th.
In related news, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total transaction of $390,000.00. Following the completion of the transaction, the director now owns 7,500 shares in the company, valued at $390,000. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the transaction, the president now owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is owned by company insiders.
Several large investors have recently modified their holdings of CRSP. BNP Paribas Arbitrage SA bought a new position in shares of Crispr Therapeutics during the second quarter worth $41,000. Aperio Group LLC bought a new position in Crispr Therapeutics during the second quarter valued at $153,000. Swiss National Bank lifted its position in Crispr Therapeutics by 28.6% during the second quarter. Swiss National Bank now owns 48,600 shares of the company’s stock valued at $2,289,000 after purchasing an additional 10,800 shares during the last quarter. Wells Fargo & Company MN lifted its position in Crispr Therapeutics by 23.9% during the second quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock valued at $28,443,000 after purchasing an additional 116,540 shares during the last quarter. Finally, Jasper Ridge Partners L.P. bought a new position in Crispr Therapeutics during the second quarter valued at $258,000. Hedge funds and other institutional investors own 49.82% of the company’s stock.
Shares of NASDAQ CRSP traded up $0.12 during midday trading on Monday, reaching $59.44. The stock had a trading volume of 1,391,345 shares, compared to its average volume of 941,091. The stock has a 50-day moving average of $65.98 and a 200-day moving average of $51.14. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. Crispr Therapeutics has a 12-month low of $28.95 and a 12-month high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. Equities analysts anticipate that Crispr Therapeutics will post 0.65 earnings per share for the current fiscal year.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
See Also: Real Estate Investment Trust (REIT) ETF
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.